Nessan Bermingham is CEO & President at Intellia Therapeutics, Inc. (NTLA). They have made 1 open-market trade across 1 company since 2017, most recently 2023-11-03.
CIK 0001377759
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NTLA | SELL | 2017-12-06 | 2017-12-08 | $20.79 | $14.0M | -19.0% | -8.1% | +48.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.